Postoperative Complications Clinical Trial
— CONTESTOfficial title:
Changes in Coagulation in Colorectal Cancer Patients Undergoing Surgical Treatment
NCT number | NCT04744688 |
Other study ID # | 1-10-72-212-20 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 6, 2021 |
Est. completion date | May 27, 2024 |
Verified date | December 2020 |
Source | University of Aarhus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) has prolonged the survival substantially for selected patients with peritoneal metastases from colorectal cancer.Bleeding and thromboembolic disease have been reported as postoperative complications related to this advanced open surgical treatment. However, perioperative changes in coagulation and fibrinolysis are only sparsely reported in the literature.The mainstay of treatment with curative intend of none-advanced colorectal cancer is minimally invasive laparoscopic surgery followed by adjuvant chemotherapy. The approach is considered associated with a lower risk of thromboembolic disease than open surgery. Despite differences in extent of surgery and thromboembolic risk the same extended thromboprophylaxis regimen for 28 days is currently prescribed to patients undergoing cytoreductive surgery with HIPEC as well as minimally invasive rectal cancer resection. This study aims to investigate all parts of the coagulation system and fibrinolysis, and thereby thromboembolic risk and potential bleeding in two groups of patients with different extent of surgical trauma: 1) Colorectal cancer patients undergoing cytoreductive surgery with HIPEC and 2) rectal cancer patients undergoing minimal invasive rectal cancer resection. Our hypothesis is that patients undergoing cytoreductive surgery with HIPEC are exposed to more aggravated alterations of coagulation and fibrinolysis than patients undergoing minimally invasive rectal cancer resection.
Status | Completed |
Enrollment | 90 |
Est. completion date | May 27, 2024 |
Est. primary completion date | December 15, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Cytoreductive surgery with HIPEC patients: - Able to give informed consent - Age = 18 years - Diagnosed with peritoneal metastases from colorectal cancer - Planned to undergo cytoreductive surgery with HIPEC Minimally invasive rectal cancer patients: - Able to give informed consent - Age = 18 years - Diagnosed with rectal cancer - Planned to undergo minimal invasive rectal cancer resection with one of: total mesorectal excision, partial mesorectal excision or abdominoperineal excision Exclusion Criteria (both groups): - Thromboembolic event within 90 days before surgery - Secondary malignancy within previous 5 years or concomitant, except non-melanoma skin cancer. |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University Hospital | Aarhus | Aarhus N |
Denmark | Thrombosis and Haemostasis Research Unit, Department for Clinical Biochemistry, Aarhus University Hospital | Aarhus N |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The difference between changes in concentration of prothrombin fragment 1+2. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in platelet concentration from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years | |
Secondary | The difference between changes in concentration of immature platelets from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years | |
Secondary | The difference between changes in concentration of plasma selectin from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years | |
Secondary | The difference between changes in activated partial thromboplastin time "APTT" (seconds) from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in international normalized ratio "INR" (seconds) from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of plasma fibrinogen from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of coagulation factor VIII from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of von wildebrand factor from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of thrombin-antithrombin complex from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in thrombin generation before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
Thrombin generation will be measured by: Lagtime (min), time to peak (min), peak thrombin (nM) and endogenous thrombin potential (nM*min). |
Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes of fibrin clot structure from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference between changes of fibrin clot structure from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
Fibrin clot structure will be measured by clot maximum, absorbance (arbitrary units), network density, lysis time (seconds), lysis area (balance between clot formation and lysis). |
Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of plasminogen activator inhibitor-1 from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of fibrin d-dimer from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in global hemostasis by Rotational thromboelastometry (ROTEM) from before surgery to the end of surgery (both groups) | The difference will be measured in blood samples from before surgery to the end of surgery (both groups).
ROTEM will include EXTEM, INTEM, FIBTEM, and APTEM by clotting time (seconds), clot formation time (seconds), alpha-angle (degrees), amplitude 10 min after clotting time (mm), maximum clot firmness (mm), lysis index 30 min after clotting time (mm), maximum lysis (mm). |
Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of syndecan-1 from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of sE-selectin from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of soluble thrombomodulin. from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of hemoglobin from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of leucocytes from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration C-reactive protein (CRP) from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection. | The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of prothrombin fragment 1+2. from the end of cytoreductive surgery to the end of HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in platelet concentration from the end of cytoreductive surgery to the end HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of immature platelets from the end of cytoreductive surgery to the end HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in activated partial thromboplastin time "aPTT" (seconds) from the end of cytoreductive surgery to the end HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in activated international normalized ratio "INR" (seconds) from the end of cytoreductive surgery to the end HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of plasma fibrinogen from the end of cytoreductive surgery to the end HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of coagulation factor VIII from the end of cytoreductive surgery to the end HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of von wildebrand factor from the end of cytoreductive surgery to the end HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of thrombin-antithrombin complex from the end of cytoreductive surgery to the end HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in thrombin generation from the end of cytoreductive surgery to the end of HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. Thrombin generation will be measured by: Lagtime (min), time to peak (min), peak thrombin (nM) and endogenous thrombin potential (nM*min). | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes of fibrin clot structure from the end of cytoreductive surgery to the end of HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. Fibrin clot structure will be measured by clot maximum, absorbance (arbitrary units), network density, lysis time (seconds), lysis area (balance between clot formation and lysis). | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of plasminogen activator inhibitor-1 from the end of cytoreductive surgery to the end of HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of fibrin d-dimer from the end of cytoreductive surgery to the end of HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of global hemostasis measured by Rotational thromboelastometry (ROTEM) from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery to the end HIPEC.
ROTEM will include EXTEM, INTEM, FIBTEM, and APTEM by clotting time (seconds), clot formation time (seconds), alpha-angle (degrees), amplitude 10 min after clotting time (mm), maximum clot firmness (mm), lysis index 30 min after clotting time (mm), maximum lysis (mm). |
Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of syndecan-1 from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of sE-selectin from the end of cytoreductive surgery to the end of HIPEC | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of soluble thrombomodulin from the end of cytoreductive surgery to the end of HIPEC | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of hemoglobin from the end of cytoreductive surgery to the end of HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of leucocytes from the end of cytoreductive surgery to the end of HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years. | |
Secondary | The difference between changes in concentration of C-reactive protein (CRP) from the end of cytoreductive surgery to the end of HIPEC. | The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. | Data will be analyzed, assessed, and presented within three years | |
Secondary | Incidence of deep vein thrombosis measured by doppler ultrasonography in colorectal cancer patients undergoing minimally invasive rectal cancer resection. | Bilateral doppler ultrasonography of the veins in the lower extremities.The scan will be performed within the postoperative period from day 3 to day 7. | Data will be analyzed, assessed, and presented within three years | |
Secondary | Incidence of deep venous thrombosis measured by doppler ultrasonography in colorectal cancer patients undergoing cytoreductive surgery with HIPEC | Bilateral doppler ultrasonography of the veins in the lower extremities.The scan will be performed within the postoperative period from day 3 to day 7. | Data will be analyzed, assessed, and presented within three years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03181620 -
Sedation Administration Timing: Intermittent Dosing Reduces Time to Extubation
|
N/A | |
Recruiting |
NCT04205058 -
Coffee After Pancreatic Surgery
|
N/A | |
Completed |
NCT06425601 -
A Comparison of Silicone Versus Polyvinylchloride (PVC) Drains Following VATS Lobectomy
|
N/A | |
Completed |
NCT02565420 -
Saline Versus Lactated Ringer's Solution: The SOLAR Fluid Trial
|
N/A | |
Recruiting |
NCT04519593 -
ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma
|
N/A | |
Completed |
NCT03662672 -
Rib Raising for Post-operative Ileus
|
N/A | |
Completed |
NCT03787849 -
Epigenetics in PostOperative Pediatric Emergence Delirium
|
N/A | |
Active, not recruiting |
NCT05886387 -
a Bayesian Analysis of Three Randomised Clinical Trials of Intraoperative Ventilation
|
||
Not yet recruiting |
NCT06351475 -
Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy
|
N/A | |
Not yet recruiting |
NCT05052021 -
The South African Coronavirus Disease of 2019 (COVID-19) Surgical Outcomes Study
|
||
Not yet recruiting |
NCT03639012 -
Outcomes of Carbohydrate Loading Paediatric Patients Preoperatively for Tonsillectomy and Adenoidectomy
|
N/A | |
Not yet recruiting |
NCT03591432 -
A Trial Comparing Transnasal humidified Rapid insufflation Ventilatory Exchange (THRIVE) and Apneic Oxygenation With Facemask Ventilation in Elderly Patients Undergoing Induction of Anaesthesia.
|
N/A | |
Not yet recruiting |
NCT03275324 -
Use of Integrated Pulmonary Index to Predict Post-Operative Respiratory Adverse Events in High Risk Patients
|
N/A | |
Recruiting |
NCT02763878 -
Uncut Roux-en-y Anastomosis Reduce Postoperative Complication and Improve Nutritional Status After Distal Gastrectomy
|
Phase 3 | |
Completed |
NCT02891187 -
Visits Versus Telephone Calls for Postoperative Care
|
N/A | |
Completed |
NCT02947789 -
Predictive Model for Postoperative Mortality
|
N/A | |
Not yet recruiting |
NCT02542423 -
Endocan Predictive Value in Postcardiac Surgery Acute Respiratory Failure.
|
N/A | |
Completed |
NCT02766062 -
Effects of Propofol and Sevoflurane on Early POCD in Elderly Patients With Metabolic Syndrome
|
N/A | |
Recruiting |
NCT01934049 -
Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty
|
Phase 4 | |
Enrolling by invitation |
NCT01744938 -
Preoperative Biliary Drainage for the Lower Malignant Obstructive Jaundice
|
Phase 3 |